Company Operations - The Company shut down operations of its USAMSA subsidiary on March 11, 2024, and plans to sell it over the next year[93]. - The Company has initiated an active search for buyers of its USAMSA operations and/or assets following the shutdown[103]. - The company shut down its USAMSA subsidiary on March 11, 2024, due to cumulative losses since inception[142]. - The company is focused on generating positive cash flow through operational reviews and strategic acquisitions[142]. Market Position - The Company estimates its share of the domestic market for antimony oxide products is approximately 4% and less than 1% in the international market[101]. - The Company is the only significant U.S. producer of antimony products, with a competitive edge due to its domestic processing capabilities[101]. - The Company has relied on foreign sources for antimony ore since 1983, with ongoing procurement from an existing supplier in Canada[100]. Financial Performance - For the three months ended September 30, 2024, total revenues increased to 2,421,020from2,063,558 for the same period in 2023, representing a growth of 17.3%[114]. - Antimony revenue for the nine months ended September 30, 2024, was 5,381,803,anincreaseof1,025,726 or 23.5% compared to 4,356,077intheprioryear[119].−GrossprofitforantimonyfortheninemonthsendedSeptember30,2024,increasedby1,210,979, or 119.9%, to 2,221,383comparedto1,010,404 in the same period of 2023[120]. - Zeolite revenue for the nine months ended September 30, 2024, was 2,280,338,anincreaseof339,329 or 17.5% from 1,941,009intheprioryear[122].−PreciousmetalsrevenueforthethreemonthsendedSeptember30,2024,was399,433, a significant increase from a loss of 5,854inthesameperiodof2023[124].−FortheninemonthsendedSeptember30,2024,preciousmetalsrevenuewas404,049, up 66.7% from 242,433intheprioryear[126].−RevenuefortheninemonthsendedSeptember30,2024,increasedto8,066,190, a 23.3% increase from 6,539,519inthesameperiodof2023[137].−Grossprofitrosesignificantlyby107.52,157,313 compared to 1,039,810intheprioryear[137].CostandExpenses−Theaveragesalespricepertonofzeolitedecreasedby12.0262 for the three months ended September 30, 2024, compared to 298inthesameperiodof2023[121].−Theaveragecostperpoundofantimonyincreasedby51.54.08 for the three months ended September 30, 2024, compared to 2.69inthesameperiodof2023[118].−Totaloperatingexpensesfortheconsolidatedentityincreasedby104.31,270,811 for the three months ended September 30, 2024, compared to 622,139in2023[133].−Totaloperatingexpensessurgedby116.03,284,706, up from 1,521,000,leadingtoalossfromoperationsof1,127,393[137]. Cash Flow and Assets - Net cash provided by operating activities improved by 1,579,764,reaching884,032 for the nine months ended September 30, 2024, compared to a cash outflow of 695,732in2023[138].−Cashflowusedbyinvestingactivitiesimprovedby1,479,106, resulting in a cash outflow of 141,708fortheninemonthsendedSeptember30,2024[140].−Cashflowusedbyfinancingactivitiesimprovedby786,640, with a net outflow of 71,139fortheninemonthsendedSeptember30,2024[141].−AsofSeptember30,2024,thecompanyhadcashandcashequivalentsof12,969,132, which are expected to cover cash requirements for the next 12 months[145]. - Total assets as of September 30, 2024, were 23,560,877,anincreasefrom21,547,455 as of December 31, 2023[117]. - The accumulated deficit increased to (40,266,104)asofSeptember30,2024,from(39,418,619) as of December 31, 2023[117]. EBITDA and Profitability - EBITDA from continuing operations was a loss of 306,853fortheninemonthsendedSeptember30,2024,comparedtoaprofitof342,071 for the same period in 2023[129]. - EBITDA for the antimony segment was a loss of 653,612forthethreemonthsendedSeptember30,2024,comparedtoaprofitof218,693 in 2023[129]. - Income (loss) from operations for the consolidated entity was a loss of 845,043forthethreemonthsendedSeptember30,2024,comparedtoalossof363,731 in 2023, representing a 132.3% increase in losses[133]. - Gross profit for the consolidated entity was 425,768forthethreemonthsendedSeptember30,2024,a64.8258,408 in 2023[133].